Recent Evidence in Epigenomics and Proteomics Biomarkers for Early and Minimally Invasive Diagnosis of Alzheimer’s and Parkinson’s Diseases
Open Access
- 1 August 2021
- journal article
- review article
- Published by Bentham Science Publishers Ltd. in Current Neuropharmacology
- Vol. 19 (8) , 1273-1303
Abstract
Background: Alzheimer’s (AD) and Parkinson’s diseases (PD) show deposits of improperly folded modified proteins. Protein expression mechanisms are involved since the early stages. Several studies evaluated epigenomics and proteomics profiles in these patients, with promising results. In general, they focused on early, specific, and minimally invasive biomarkers for the diagnosis and prognosis of AD and PD. Objective: This review aimed at summarizing results to find the most reliable evidence in the field. Results: Among epigenomics studies, there is a focus on microRNAs (miRNAs) as candidate diagnostic biomarkers for AD or PD from blood samples like miR-342-3p, miR-107, miR-106a-5p, miR-106b- 5p, miR-195, and miR-19b. In addition, DNA methylation has been tested in a few works, obtaining significant differences in some genes (NCAPH2/LMF2 COASY, SPINT1, BDNFTREM1, TREM2, NPAS2, PDE4D), which could be useful for evaluating the disease progression as well as potential risk factors. Regarding proteomics, most of the studies were untargeted and used plasma or serum samples. In general, they highlighted the importance of coagulation, inflammation pathways, and oxidative stress. Among targeted studies, some proteins (phosphorylated tau, C reactive protein (CRP), interleukins, necrosis factors, transferrin, glial fibrillary acidic protein (GFAP), and neurofilaments) showed different plasma levels in AD and PD patients in comparison with healthy participants. Finally, a few studies have identified specific-AD and PD epigenetic and proteomic biomarkers (ApoE and oxidized DJ-1) in comparison with other similar pathologies. Conclusion: In general, there is a common lack of clinical validation of these potential biomarkers because of which its use in clinical practice is still limited.Keywords
Funding Information
- Health Institute Carlos III (Spanish Ministry of Economy, Industry and Innovation (FIS PI19/00570)
- Health Institute Carlos III (Spanish Ministry of Economy, Industry and Innovation) (CP16/00082)
This publication has 100 references indexed in Scilit:
- Sirtuin1: A Promising Serum Protein Marker for Early Detection of Alzheimer’s DiseasePLOS ONE, 2013
- Soluble amyloid precursor protein β as blood-based biomarker of Alzheimer’s diseaseTranslational Psychiatry, 2013
- Plasma Biomarkers Associated With the Apolipoprotein E Genotype and Alzheimer DiseaseArchives of Neurology, 2012
- Targeting of the Arpc3 actin nucleation factor by miR-29a/b regulates dendritic spine morphologyJournal of Cell Biology, 2011
- miR-29b is activated during neuronal maturation and targets BH3-only genes to restrict apoptosisGenes & Development, 2011
- Decreased C-Reactive Protein Levels in Alzheimer DiseaseJournal of Geriatric Psychiatry and Neurology, 2009
- Loss of microRNA cluster miR-29a/b-1 in sporadic Alzheimer's disease correlates with increased BACE1/β-secretase expressionProceedings of the National Academy of Sciences, 2008
- Variation in the miRNA-433 Binding Site of FGF20 Confers Risk for Parkinson Disease by Overexpression of α-SynucleinThe American Journal of Human Genetics, 2008
- Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene databaseNature Genetics, 2007
- Cell biology of protein misfolding: The examples of Alzheimer's and Parkinson's diseasesNature Cell Biology, 2004